Doximity Handed Its President 150,000 Options Last Month. Here's What the Latest Filing Signals for Investors

Steven L. Zatz, the president of Doximity, Inc. (NYSE:DOCS), disposed of 4,482 shares of Class A Common Stock on August 15, according to a recent SEC Form 4 filing.

Transaction summary

Metric	Value
Transaction value	$111,154
Shares sold (direct)	4,482
Post-transaction shares (directly held)	51,864
Post-transaction value	$1.29 million

Transaction value based on SEC Form 4 weighted average sale price ($24.80).

Key questions

• What was the specific mechanism for this share disposal?
  The disposition was a non-discretionary sell-to-cover transaction to satisfy tax withholding requirements upon the vesting of restricted stock units, a routine procedure for executive equity compensation.
• How does this impact the insider's total equity position?
  Following the disposal of 4,482 shares, Zatz maintains direct ownership of 51,864 shares of Class A Common Stock.
• What is the company's current financial profile and valuation?
  As of the August 14 market close, Doximity has a market capitalization of $4.6 billion, supported by trailing 12-month revenue of $655.6 million and net income of $167.0 million.
• What was the market value of the remaining position at the time of the trade?
  Based on the August 14 market close of $24.80, the president's remaining 51,864 directly held shares represent a market value of $1.29 million.

Company Overview

Metric	Value
Share Price (as of market close 2026-08-14)	$24.80
Market Capitalization	$4.6 billion
Revenue (TTM)	$655.6 million
Net Income (TTM)	$167.0 million

Company Snapshot

• Doximity operates a cloud-hosted digital platform that provides healthcare practitioners with specialized tools for peer connectivity, patient care coordination, remote consultations, access to medical research, and professional development.
• The company generates revenue through subscription-based services and licensing arrangements with pharmaceutical companies and healthcare organizations that utilize the platform to engage with medical professionals.
• The primary customer base consists of pharmaceutical companies seeking to reach physicians and healthcare organizations seeking to optimize clinical workflows and practitioner engagement across the United States healthcare system.

Doximity is a leading digital health platform serving the U.S. healthcare practitioner community with approximately 880 employees and a market capitalization of $4.6 billion. The company has achieved substantial profitability with TTM net income of $167.0 million on revenue of $655.6 million, demonstrating strong unit economics and operational efficiency. Doximity's competitive advantage derives from its comprehensive practitioner network, integrated suite of clinical and professional tools, and established relationships with pharmaceutical and healthcare organization customers.

What this transaction means for investors

Zatz runs the operating side of a company in the middle of rewiring what it sells. He holds 51,864 shares outright, roughly $1.3 million, and the withholding here barely dented it, but his real exposure is the 150,000 options Doximity granted him on July 22 at a $20.49 strike, which don't start vesting until July 2027. They're not noted in this insider filing, but a separate one late last month when the grant happened. That's important because he effectively only gets paid if the stock climbs from there.

The timing is prescient given Doximity's recent results. Revenue grew 7% to $156.6 million in the June quarter and management raised the full-year range, but AI compute costs pulled gross margin down to 87.5% from 91.2%, and adjusted EBITDA fell 6% to $74.8 million. CFO Matt Sonefeldt told analysts on August 6 that "higher-than-expected AI usage creates a good problem for Doximity." Higher-than-expected usage with the contracted AI search revenue not recognized until the third quarter is indeed a good problem, but it'll be important to see whether and how much margins improve once that revenue starts coming in.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity. The Motley Fool has a disclosure policy.